CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia
- 2 October 2017
- journal article
- research article
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 142 (1) , 64-69
Abstract
Context.—: Urinary bladder flat carcinoma in situ (CIS) is a worrisome lesion, requiring aggressive surveillance and treatment. Cytokeratin 20 (CK20) and p53 are common immunohistochemical antibodies used to supplement CIS diagnosis in biopsy samples. However, existing data come primarily from unequivocally benign and malignant specimens. Objective.—: To correlate these markers in specimens with borderline histology with outcomes. Design.—: CK20 and p53 immunohistochemistry was analyzed for staining pattern, classified as CIS pattern (both stains yielding strong labeling of the area of concern), discordant (only 1 stain yielding CIS pattern), indeterminate (1 or both stains yielding partial or equivocal labeling), or benign (both stains yielding a benign pattern). Results.—: Specimens with equivocal atypia (n = 69) from 65 patients were studied. There were 9 specimens (13%) that had a CIS staining pattern, 18 (26%) were discordant, 31 (45%) were indeterminate, and 11 (16%) were benign. Of the discordant specimens, 13 labeled for CK20 but not p53, whereas 5 showed the opposite. Most specimens (n = 47; 68%) were obtained from patients with a known history of bladder cancer, of which recurrence developed in 27, with an average interval of 37 months (range, 2–216 months). A subset (n = 22; 34%) had no prior history of bladder cancer, from which only 1 patient with CK20-positive/p53-equivocal staining later developed diagnostic carcinoma. Conclusions.—: In our cohort of specimens with equivocal urothelial atypia, very few patients without a prior diagnosis of bladder cancer progressed to diagnostic cancer (1 of 22), suggesting that staining results should be interpreted with caution in de novo atypia. Patients with a known history of bladder cancer had a substantial rate of recurrence, independent of staining pattern.Keywords
This publication has 25 references indexed in Scilit:
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline ChemotherapyCancer Cell, 2014
- The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/NeuAnnals of Diagnostic Pathology, 2014
- ICUD-EAU International Consultation on Bladder Cancer 2012: PathologyEuropean Urology, 2013
- Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: The state of the artCritical Reviews in Oncology/Hematology, 2010
- Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsiesDiagnostic Pathology, 2009
- Immunohistochemical Expression of CK20, p53, and Ki-67 as Objective Markers of Urothelial DysplasiaLaboratory Investigation, 2003
- Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International ConsultationVirchows Archiv, 2001
- Discriminatory Immunohistochemical Staining of Urothelial Carcinoma in Situ and Non-neoplastic UrotheliumAmerican Journal of Surgical Pathology, 2001
- The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary BladderAmerican Journal of Surgical Pathology, 1998
- Cytokeratin 20 as an objective marker of urothelial dysplasiaBritish Journal of Urology, 1996